CDMOs, OEMs, and Used Equipment Resellers are Joining Forces to Onshore Pharmaceutical Manufacturing


The US pharmaceutical industry is making a concerted effort to bring a greater share of drug production onshore. Over the past several decades, pharmaceutical manufacturing has increasingly moved offshore, driven in part by lower manufacturing costs and other economic advantages.1 The COVID-19 pandemic highlighted vulnerabilities in these increasingly global pharmaceutical supply chains and reinforced concerns about the resilience of US drug manufacturing.2 At the same time, US dependence on foreign sources for APIs and key starting materials, including significant manufacturing capacity in China and India, has become an increasing national security concern.3

To encourage onshoring, the current administration imposed tariffs under Section 232 of the Trade Expansion Act of 1962, establishing a 100% default rate on imported patented pharmaceuticals, with reductions available based on commitments to US manufacturing and other factors.4 Together, these policies are increasingly making offshore dependence a financial and regulatory liability.

APIs are particularly difficult to onshore because the United States has limited domestic production capacity, and building new capacity requires significant capital, specialized infrastructure, technical expertise, and time.

Although onshoring presents substantial challenges, efforts are advancing, and pharmaceutical companies are assessing the best paths for their organizations. Some are making substantial investments in domestic manufacturing infrastructure. Lilly, for example, has committed more than $50 billion to expanding US manufacturing since 2020, including multiple new facilities dedicated to API production.5 Others are turning to domestic manufacturing partners. Lifecore Biomedical, for example, announced an agreement in 2025 to transfer commercial manufacturing of an injectable pharmaceutical product from overseas facilities to its US operations.6 In September 2026, Lifecore signed the agreement to handle the technical transfer for commercial manufacturing, and revenue is expected by 2028.7

The Case Against Building

Building domestic facilities is a natural impulse for pharmaceutical companies looking to bring manufacturing onshore. But building a pharmaceutical manufacturing facility entails steep costs and difficult economic, regulatory, and timeline trade-offs.

Costs vary widely, from $500 million for a small-volume facility producing low-complexity products to $6.5 billion or more for a high-volume facility producing complex, advanced therapeutics.8 Timelines are equally daunting, as a new facility typically takes 5 to 10 years to come online, from groundbreaking through validation and regulatory approval.9

In theory, it is easier to justify building a plant for a patent-protected drug with higher margins than for low-cost generics; however, by the time a plant is built and running, much of the drug’s patent life has already expired, which cuts into the returns that made the investment attractive.

Labor is another constraint, specifically a shortage of workers with pharmaceutical or biopharmaceutical experience in certain regions of the US. Industry research estimates that roughly 60,000 biopharma manufacturing jobs in the US remain unfilled, and 80% of pharmaceutical manufacturers report a substantial gap between their workforce’s current capabilities and the digital skills modern operations require.10

Equipment acquisition timelines add another layer of complexity. The multi-year backlogs that plagued industrial machinery during and after the COVID-19 pandemic have largely eased, but new bottlenecks have emerged, driven by geopolitical factors, material shortages, and surging demand for advanced biologic and sterile filling equipment.

Given these challenges, many pharmaceutical companies are turning to CDMOs and CDMOs with available gray space are especially attractive.

CDMOs with Available Gray Space

A CDMO partnership can make onshoring less difficult. There’s no capital outlay; staffing and talent issues become the CDMO’s responsibility, and the regulatory groundwork, including quality systems, standard operating procedures, and established FDA relationships, is already in place.

The real challenge is finding a CDMO partner with the right capabilities, equipment, capacity, and flexibility. For many companies working to onshore, one solution is to choose a CDMO with ample gray space and strong relationships with resellers of used equipment.

Gray space is unbuilt area adjacent to or within an operational, registered good manufacturing practice (GMP) pharmaceutical manufacturing facility. This space is not yet outfitted with equipment or utilities. However, it sits within or is attached to a facility or campus that already holds the necessary FDA registration, established quality systems, and existing site infrastructure. A CDMO can generally expand into its gray space quickly because the infrastructure is already in place, allowing it to respond rapidly to client needs and sudden shifts in capacity demands.

In short, CDMOs with gray space offer much of the same flexibility as a pharmaceutical company would enjoy by building its own facility, with the advantage of no capital outlay and CDMO management.

The Path to Rapidly Equipping Gray Space

New equipment from major original equipment manufacturers (OEMs) can take 18 to 36 months to arrive, and even a straightforward new tablet press typically requires 10 to 12 months to build. Used equipment dealers can significantly shorten that timeline, enabling CDMOs to equip available manufacturing space more quickly and respond to customer demand.

The pharmaceutical industry already offers many examples of redeploying manufacturing assets. When Par Pharmaceuticals, an Endo company, closed its pharmaceutical manufacturing campus in Huntsville, Alabama, Federal Equipment Company and its partners acquired the 110-acre site and worked to redeploy its manufacturing infrastructure and equipment. The site ultimately became home to CDMO operations under TriRx Pharmaceutical Services, demonstrating how existing pharmaceutical assets can be repurposed rather than recreated from the ground up.11

When the right equipment is already available, a CDMO can acquire and install it in a fraction of the time required to order a new machine. Equipment held in inventory can often ship within days or weeks after inspection and any required refurbishment, although installation, qualification, and validation timelines ultimately depend on the equipment, facility, process, and the CDMO’s quality requirements.

In this model, the CDMO and the used equipment dealer complement each other. The CDMO provides manufacturing space, technical expertise, and the regulatory and quality infrastructure required to operate the equipment. The used equipment dealer provides access to existing pharmaceutical manufacturing assets, potentially reducing both procurement time and capital requirements. OEMs can further support the process with parts, upgrades, installation, qualification support, and ongoing maintenance.

Collaboration Between CDMOs, Used Equipment Dealers, and OEMs

Pharmaceutical manufacturers used to face a clear choice: buy new equipment from an OEM or buy used equipment. Rather than viewing each other as competitors, reputable used equipment dealers and OEMs now work with CDMOs to meet clients’ needs.

When pre-owned equipment remains supported by the OEM, the OEM may provide key technical support, including replacement parts, upgrades, installation and maintenance services, and documentation and technical assistance for equipment requalification. The OEM still earns service revenue under this arrangement, and if the CDMO later needs additional equipment, established brand loyalty often leads to new equipment sales.

Free Training

Source link

Company that makes equipment for computer chip manufacturing commits $1.5B in Tualatin, breaks ground on new lab



FILE - The inside of a computer is seen on Feb 23, 2019, in Jersey City, N.J. A global computer chip shortage has made it harder for consumers to get their hands on cars, computers and other modern-day necessities, so Congress is looking to boost chip manufacturing and research in the United States with billions of dollars from the federal government.

FILE – The inside of a computer is seen on Feb 23, 2019, in Jersey City, N.J. A global computer chip shortage has made it harder for consumers to get their hands on cars, computers and other modern-day necessities, so Congress is looking to boost chip manufacturing and research in the United States with billions of dollars from the federal government.

Jenny Kane / AP

A company vital in designing and building equipment for the world’s largest computer chip firms broke ground on a $620 million research and development lab in Tualatin Wednesday.

Overall, Lam Research will spend $1.5 billion on major research and development laboratories in Washington County over the next decade and half.

It’s part of a global expansion of the semiconductor equipment firm’s network of labs. Lam Research plans to pump $3 billion into operations in the U.S., as well as in Asia and Europe.

“In the AI era, the pace of innovation is relentless, requiring chips with new architectures, different materials, and complex features engineered with nanoscale precision,” Lam Research CEO Tim Archer said in a written statement earlier this month about the $3 billion global investment. “Our ability to increase velocity throughout the research and development process has become a decisive advantage.”

Wednesday’s groundbreaking comes at a precarious time for the state’s manufacturing sector, which includes semiconductor manufacturing. The sector has been shedding jobs as companies consolidate. Oregon has lost nearly 8,500 manufacturing jobs over the last year, according to state employment data.

Those losses include nearly 2,500 layoffs last summer at major chipmaker Intel, the state’s largest private employer. Lam Research designs and builds tools for Intel and other major semiconductor companies, like Micron.

Lam Research's groundbreaking ceremony on its new research & development lab in Tualatin, Oregon. The facility is expected to create 400 jobs at the semiconductor equipment company.

Lam Research’s groundbreaking ceremony on its new research & development lab in Tualatin, Oregon. The facility is expected to create 400 jobs at the semiconductor equipment company.

Kyra Buckley / OPB

The job losses come despite soaring demand for computer chips due to advancement in the use of artificial intelligence. Intel, which acts as an anchor company for Oregon’s industry that’s mainly concentrated in Washington County, is playing catch-up to other companies when it comes to AI.

But recent partnerships now have Intel providing chips for data centers, needed to keep the AI industry running. Experts say that won’t necessarily translate into big jobs gains for Oregon’s technology manufacturing sector. However, it does raise confidence for equipment companies like Lam Research that their products will be in demand for the foreseeable future.

Lam currently employs around 3,000 people, mostly at its campus in Tualatin. Once constructed, the new 120,000 square foot facility is expected to add another 400 jobs to the company’s headcount. Under a multi-year deal with Washington County, the new building qualifies for property tax breaks and Lam will pay an estimated $111 million in taxes and fees over the life of the agreement.

“Our new advanced Oregon lab is expected to deepen our specialized capabilities and add tens of thousands of square feet of valuable cleanroom space,” Sesha Varadarajan, Lam’s chief operating officer, said in written statement about Wednesday’s groundbreaking, “enabling even closer collaboration with customers while strengthening the expertise and reach of our global lab network.”

Free Training

Source link

Siemens, Jabil expand electrical equipment manufacturing


Siemens and Jabil Inc. (NYSE: JBL) recently announced plans to operate a new manufacturing facility at the Crosspointe Logistics Center in Prince George County, Va., supporting the energy infrastructure industry. As demand for power infrastructure continues to accelerate, particularly driven by rapid growth in data centers and electrification, this investment will help expand capacity and increase how quickly new infrastructure can be brought online. The Prince George facility, operated by Jabil, will feature approximately 300,000-square-feet of modern industrial space, allowing Siemens to expand U.S. production capacity for its medium-voltage switchgear and integrated power delivery solutions. This facility will expedite the availability of critical equipment needed to energize new infrastructure.

The $30 million investment will go towards scaling-up equipment, tooling, production readiness and operations at the Virginia site. The facility will produce the advanced systems and solutions necessary to protect, control and safely operate equipment in data center, utility, and industrial power generation and distribution applications. With production slated to begin in fall 2026, the Prince George facility is expected to add at least 350 jobs once operational.

“Our data center, utility and industrial customers are under intense pressure to add capacity quickly, with less risk and more predictability,” said Brian Dula, President of the Electrification and Automation business unit at Siemens Smart Infrastructure USA. “By adding additional avenues to expand dedicated manufacturing of Siemens‑designed switchgear and power delivery solutions here in the U.S., we’re helping customers shorten project timelines and improve delivery confidence — while reinforcing a resilient domestic supply chain.”

“Our new Prince George facility will help us build the energy management solutions Siemens needs to meet customers’ growing power requirements with greater speed and scale,” said Brent Tompkins, SVP, Global Business Units, Renewables and Energy Infrastructure, at Jabil. “We’re proud to collaborate with Siemens to expand Jabil’s capabilities within the United States and enable the world’s most important technologies.” Recently achieving a $1 billion manufacturing investment milestone, this expansion reflects Siemens’ continued focus on strengthening domestic supply chains, reindustrializing the U.S. and adding capacity to meet accelerating demand for critical power infrastructure. This will allow Siemens to expand its leadership position in the electrification of data centers and the related grid infrastructure. For Jabil, this investment adds to the company’s growing U.S. manufacturing footprint, spanning more than 30 sites with proven experience and investments in automation, robotics, and process optimization to support production at scale across industries.

Jabil is one of the world’s largest manufacturing solutions providers and has worked with Siemens across the globe for numerous years, supporting high standards for quality and delivery performance. The Prince George collaboration builds on that foundation to help Siemens scale production in the U.S. while maintaining rigorous oversight and adherence to Siemens’ specifications and quality requirements, delivering essential power infrastructure at the pace demand now requires.

To learn more about career opportunities at the Prince George facility, click here.

Free Training

Source link

Industrial equipment leader for US manufacturing


SPX FLOW Inc provides pumps, valves and mixers essential for food, beverage and industrial processing, with strong exposure to US markets amid ongoing supply chain recovery.

SPX FLOW Inc, a key supplier of engineered equipment for food and beverage processing, recently reported steady demand in its core segments. The company, listed on the New York Stock Exchange under ticker FLOW, serves major US producers with solutions for mixing, blending and heat transfer. Its products support efficiency in manufacturing plants across North America.

The stock traded at approximately 50.25 USD on 05/13/2026 on NYSE, reflecting stability in the industrial sector, according to Yahoo Finance as of 05/13/2026. Investors track SPX FLOW for its role in resilient supply chains vital to US consumer goods production.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

  • Name: SPX FLOW Inc
  • Sector/industry: Industrial Machinery & Equipment
  • Headquarters/country: United States
  • Core markets: North America, Europe
  • Key revenue drivers: Food & Beverage, Power & Energy
  • Home exchange/listing venue: NYSE (FLOW)
  • Trading currency: USD

SPX FLOW: core business model

SPX FLOW designs and manufactures process equipment for applications including homogenization, heat exchangers and dryers. Its portfolio targets the food and beverage industry, where precision mixing ensures product quality for dairy, beverages and bakery goods. The company also serves power generation and chemical processing with pumps and valves built for high-pressure operations.

Headquartered in Charlotte, North Carolina, SPX FLOW operates globally but derives a significant portion of revenue from US customers. For the fiscal year 2025, reported on 02/27/2026, net sales reached 1.45 billion USD, with Food & Beverage contributing 58%, according to SPX FLOW investor site as of 02/27/2026. This segment benefits from US food safety regulations driving equipment upgrades.

Main revenue and product drivers for SPX FLOW

The Food & Beverage division leads with products like APV pumps and mixing systems used by processors such as dairy giants and soft drink makers. In Q4 2025, this unit posted 8% organic growth, fueled by demand for sustainable processing tech amid US sustainability mandates. Industrial segment follows, providing solutions for oil & gas and chemicals.

Key drivers include aftermarket parts and services, which offer high-margin recurring revenue. For 2025 full year, adjusted EBITDA margins hit 17.2%, published with Q4 results on 02/27/2026 per company filings. US manufacturing resurgence supports orders as plants modernize post-pandemic.

Industry trends and competitive position

The industrial processing equipment market grows with US food production output, projected at 3-4% CAGR through 2028 per S&P Global as of 01/2026. SPX FLOW competes with Alfa Laval and GEA Group, differentiating via US-centric service networks that reduce downtime for domestic clients.

Sustainability trends favor its energy-efficient heat exchangers, aligning with EPA guidelines. The company’s 2025 sustainability report highlighted 15% reduction in product energy use, enhancing appeal to US firms facing carbon reporting rules.

Why SPX FLOW matters for US investors

SPX FLOW’s NYSE listing and US headquarters provide direct exposure to American industrial recovery. Over 50% of revenue ties to North America, linking performance to US GDP growth and manufacturing PMI. Its dividend yield around 1.2% as of Q1 2026 adds income stability for retail portfolios.

Conclusion

SPX FLOW maintains a solid position in industrial processing equipment, with Food & Beverage driving growth amid US market demands. Recent financials show margin expansion and stable orders, though sector cycles warrant monitoring. The company’s US focus offers retail investors a play on domestic manufacturing strength without overseas volatility.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.

Free Training

Source link

Tesla (TSLA) reportedly in talks to buy $2.9B in Chinese solar equipment for 100 GW US push


FERC July 2025
Image: Tesla

Elon Musk’s plan to build 100 GW of solar manufacturing capacity in the United States just got its first major price tag: $2.9 billion in equipment from Chinese suppliers, according to a Reuters exclusive.

If the deal closes, it marks the biggest concrete investment yet in Musk’s solar ambitions, and a stunning reversal for a company that effectively abandoned its solar business just two years ago.

The deal

Reuters reports that the equipment is valued at roughly 20 billion yuan ($2.9 billion) and that Tesla is in discussions with multiple Chinese suppliers. The frontrunner is Suzhou Maxwell Technologies, a Shenzhen-listed company that dominates the global market for solar cell screen-printing production lines.

Other potential suppliers include Shenzhen S.C New Energy Technology and Laplace Renewable Energy Technology.

Advertisement – scroll for more content

The Chinese companies have been told to deliver the equipment before this autumn, with at least two sources indicating it would be shipped to Texas. That aligns with Tesla’s expanding Texas manufacturing footprint, which already includes its Austin Gigafactory and a new Houston Megafactory under construction for Megapack production.

One significant hurdle remains: Suzhou Maxwell needs export approval from China’s commerce ministry, and it’s unclear how quickly that clearance will come. Beijing has been tightening its grip on solar technology exports over the past two years, and China’s commerce ministry recently made export controls a top priority for 2026.

On the US side, the equipment faces a more favorable regulatory path. Solar manufacturing equipment was excluded from Section 301 tariffs in 2024 at the urging of American solar panel makers, and that exemption has been extended by the Trump administration through November 2026.

The 100 GW ambition

The $2.9 billion equipment purchase is tied directly to a goal Musk laid out at the World Economic Forum in Davos in January 2026. There, he announced that both Tesla and SpaceX are independently working to build 100 GW per year of solar manufacturing capacity in the US — covering the entire supply chain from raw materials to finished panels.

The company’s own job listings reinforce the scale of the ambition, explicitly referencing a target of 100 GW of “solar manufacturing from raw materials on American soil before the end of 2028.”

For context, total US solar installations in 2023 reached about 32 GW. Tesla wants to manufacture more than three times that, every single year, on its own.

The driving force behind the urgency isn’t climate policy, it’s AI. Data center construction and the broader electrification of transportation pushed US power consumption to a second consecutive record in 2025, and the projections keep rising. Musk has argued that no other energy source can scale fast enough or cheaply enough to meet those demands.

Tesla’s troubled solar history

The irony is thick. Tesla acquired SolarCity for $2.6 billion in 2016 and promised to revolutionize the residential solar market with its Solar Roof tiles. Musk set a target of 1,000 new solar roofs per week by the end of 2019. Tesla never came close. By Q2 2022, the company was deploying approximately 23 roofs per week — roughly 2% of the target.

Today, Tesla never talks about its solar roof; it’s essentially a dead product.

Tesla’s solar deployment declined steadily after the SolarCity acquisition. Panasonic, which had partnered with Tesla at the Buffalo Gigafactory to manufacture solar cells, exited the facility in 2020. By late 2024, Tesla stopped reporting solar deployment altogether, and the word “solar” didn’t appear once during the company’s Q3 2024 earnings call.

There were signs of a revival in early 2026 when Tesla launched a new US-made solar panel (the TSP-420) assembled at the Buffalo factory, featuring a proprietary 18-zone power optimization system. But the scale was modest — initial capacity at the Buffalo facility was just over 300 MW per year, a rounding error compared to the 100 GW target.

Energy storage is a different story

While Tesla’s solar business withered, its energy storage division exploded. Tesla deployed a record 46.7 GWh of energy storage in 2025, a 48% increase year-over-year, generating $12.8 billion in revenue with a 29.8% gross margin — nearly double what Tesla earns selling cars.

Energy storage now accounts for 13% of Tesla’s total revenue and 23% of its gross profit. The Lathrop Megafactory in California produces Megapacks at its full planned capacity of 40 GWh per year, and the new Houston facility targets 50 GWh of annual output by end of 2026.

The solar manufacturing push would complement this storage infrastructure — Tesla could theoretically pair its own solar panels with Megapacks and Powerwalls for integrated energy solutions, and potentially use the output to power its own operations and even SpaceX satellites.

Electrek’s Take

We’ve been tracking Tesla’s solar journey since the SolarCity acquisition, and the trajectory has been one of consistent underdelivery. The Solar Roof never materialized at scale. Solar deployments cratered. The entire solar business segment became an afterthought as energy storage consumed all of Tesla’s energy division attention.

So when Musk announced a 100 GW solar manufacturing target at Davos, our first instinct was skepticism — and it still is. Going from roughly 300 MW of annual solar panel capacity at the Buffalo factory to 100 GW is a staggering 300x increase, on a timeline of less than three years.

That said, the $2.9 billion equipment purchase suggests this isn’t just talk. That’s real capital being deployed (or at least negotiated), and the autumn delivery deadline for equipment in Texas suggests Tesla intends to move fast. The company also has genuine tailwinds: the tariff exemption on solar manufacturing equipment, surging electricity demand from AI data centers, and a proven energy division that can integrate solar with its storage products.

The biggest risks are execution, Tesla’s solar track record is dismal, and the Chinese export approval, which Beijing could use as leverage in the ongoing trade tensions. We’ll believe the 100 GW target when we see equipment on the ground and production lines running.


Add Electrek as a preferred source on Google
Add Electrek as a preferred source on Google

FTC: We use income earning auto affiliate links. More.

Free Training

Source link

Meyer Burger equipment purchase enables Solestial US manufacturing shift


Solestial, a US-based space solar manufacturer, has acquired solar manufacturing equipment from Meyer Burger to strengthen domestic manufacturing operations in the US. The acquisition enables Solestial to process its silicon solar technology from wafer to cell in house. Equipment was acquired from Meyer Burger’s Hohenstein-Ernstthal facility in Germany, where Solestial’s wafers had previously been processed. Solestial has stated that it plans to shift limited solar cell manufacturing activities from Germany to the US. The Solestial has confirmed that its 30,000 square foot US facility is operational and commissioned for production. The move follows the disruption of a prior manufacturing partnership after Meyer Burger’s German subsidiaries filed for insolvency in May 2025. Recently, Solestial has partnered with NASA Glenn Research Center to advance ultrathin silicon solar array performance through technical testing.

Free Training

Source link